Results 111 to 120 of about 1,682,259 (274)
Mechanisms and treatment of obesity in polycystic ovary syndrome
, 2008 Mechanisms and treatment of obesity in polycystic ovary ...
GAMBINERI, ALESSANDRA +3 more
core +1 more source
Cumulative isotretinoin dosing, treatment response and acne relapse: A randomized controlled trial
Journal of the European Academy of Dermatology and Venereology, EarlyView.In this randomized controlled trial, cumulative isotretinoin doses of 120 and 150 mg/kg showed similar relapse rates at 12 months. Both regimens achieved substantial and comparable reductions in inflammatory acne lesions across the face, chest and back.
Ruggero Cascio Ingurgio +16 more
wiley +1 more source
Insulin resistance. Definition and epidemiology in normal women and polycystic ovary sindrome women
, 2007 Insulin resistance.
GAMBINERI, ALESSANDRA, PASQUALI, RENATO
core +1 more source
, 2017 Anderson Sanches de Melo, Rosana Maria dos Reis, Rui Alberto Ferriani, Carolina Sales Vieira Department of Gynecology and Obstetrics, Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, Sã
Vieira CS +3 more
core
Voice characteristics associated with polycystic ovary syndrome
, 2016 Objectives/HypothesisTo test the assumption that voice is changed in polycystic ovary syndrome (PCOS) and identify changes that ...
Demir, Mehmet Gökhan +6 more
core +1 more source
Polycystic ovary syndrome [PDF]
Human Reproduction, 1996 R, Homburg, L C, Giudice, R J, Chang
openaire +2 more sources
Nursing, 2019 Abstract: Polycystic ovary syndrome (PCOS) is a common endocrine disorder. Patients may present with a combination of hyperandrogenism symptoms, menstrual irregularities, metabolic syndrome, infertility, acne, and obesity. PCOS diagnosis is based on three diagnostic guidelines. Treatment options include oral contraceptive pills, antiandrogens,
openaire +3 more sources
Modulation of sebocyte function in acne: A pathway‐inclusive review
Journal of the European Academy of Dermatology and Venereology, EarlyView.Acne is multifactorial, with the sebocyte acting as a central immunometabolic hub linking lipogenic, inflammatory, hormonal and barrier pathways. Mapping established and investigational therapies onto this sebocyte‐centred model offers a mechanism‐based framework that complements existing treatment paradigms and may guide more targeted, antibiotic ...
Christos C. Zouboulis +3 more
wiley +1 more source
Pathogenesis of hidradenitis suppurativa: From susceptibility to chronicity
Journal of the European Academy of Dermatology and Venereology, EarlyView.This review describes hidradenitis suppurativa as a heterogeneous disorder in which genetic susceptibility, epithelial dysfunction, environmental exposures, immune activation and microbial ecology converge differently across patients and disease stages.
Kelsey R. van Straalen +5 more
wiley +1 more source
Obesity‐associated transcriptomic remodelling in hidradenitis suppurativa and treatment response
Journal of the European Academy of Dermatology and Venereology, EarlyView.This review highlights that adiposity systemically primes HS through adipokine dysregulation and insulin resistance, contributing to lesional metabolic reprogramming and perilesional barrier dysfunction. Current evidence indicates that obesity exacerbates disease severity and attenuates responses to biologic therapies, supporting the classification of ...
Sahil Kapur +9 more
wiley +1 more source